Gene · 51428
Papers1,824
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,824
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Expansive spatial pattern of Aβ deposition in patients with cerebral amyloid angiopathy: A three-dimensional surface-to-depth analysis. | Sci Adv | 2026 | 41650268 | PubTator, text mining | PubMed |
| Biallelic germline variants in the hematologic malignancy predisposition gene DDX41 cause retinal dystrophy through dysregulation of retinal homeostasis. | medRxiv | 2026 | 41646732 | PubTator, text mining | PubMed |
| Correction to: Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis. | Ann Hematol | 2026 | 41636891 | PubTator, text mining | PubMed |
| CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial. | Blood Adv | 2026 | 41628350 | PubTator, text mining | PubMed |
| Self-aggregating Lactiplantibacillus plantarum enhances type-I interferon responses via the cytosolic sensors NOD2 and cGAS. | Gut Microbes | 2026 | 41605865 | PubTator, text mining | PubMed |
| STING single amino acid polymorphisms modulate iridovirus immune evasion and pathogenicity spectrum. | Proc Natl Acad Sci U S A | 2026 | 41576079 | PubTator, text mining | PubMed |
| DDX41-Mutated AML: A Case Report and Perspectives. | JCO Precis Oncol | 2026 | 41564377 | PubTator, text mining | PubMed |
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood Neoplasia | 2026 | 41536779 | PubTator, text mining | PubMed |
| NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort. | Hematol Oncol | 2026 | 41527965 | PubTator, text mining | PubMed |
| DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study. | Leukemia | 2026 | 41339477 | PubTator, text mining | PubMed |
| The dynamic alterations of DDX41 mutations in patients with myelodysplastic neoplasms treated with lenalidomide. | Leuk Lymphoma | 2026 | 41231391 | PubTator, text mining | PubMed |
| How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know. | J Clin Med | 2025 | 41464583 | PubTator, text mining | PubMed |
| Application of the Richards function to serum antibody titration. | Front Immunol | 2025 | 41459540 | PubTator, text mining | PubMed |
| Low Rate of Germline Investigation for Variants of Suspected Germline Origin Detected During the Diagnostic Work-Up of Myeloid Neoplasms. | EJHaem | 2025 | 41409737 | PubTator, text mining | PubMed |
| Possibilities of Using 3D Printing with Polymers as Structural Components. | Materials (Basel) | 2025 | 41374226 | PubTator, text mining | PubMed |
| Structural Characterization of Protein-Nucleic Acid Complexes: An Overview of the Recent Innovation in the Analytic Methods. | Int J Mol Sci | 2025 | 41373622 | PubTator, text mining | PubMed |
| Clinical and Molecular Spectrum of DDX41 Variants in Korean Patients with Hematologic Malignancies. | J Clin Med | 2025 | 41303035 | PubTator, text mining | PubMed |
| Oncogenic DEAD-box ATPase DDX41 establishes transcript ensembles via CLK3-dependent and -independent mechanisms. | Nat Commun | 2025 | 41193510 | PubTator, text mining | PubMed |
| PRRs-Dependent and Independent Mechanisms of STING Signaling in Inflammatory and Autoimmune Diseases. | Biomedicines | 2025 | 41153813 | PubTator, text mining | PubMed |
| Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification. | Leuk Res Rep | 2025 | 41146867 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51428/papers?page=3